Dr. Marc Remke

Research group leader within the German Cancer Consortium (DKTK)
Pediatric Neuro-Oncogenomics

Medical Faculty

Contact:
Phone: 0211 81-19253
Email: undefinedmarc.remke@med.uni-duesseldorf.de
undefinedWebsite

Academic Career and Research Areas

The research group of Dr. Marc Remke aims to characterize tumor-specific alterations affecting the coding and non-coding genome to refine existing or develop novel tumor treatment strategies. Specifically, the group performs genome-wide profiling and next-generation sequencing studies paired with functional modeling to identify oncogenic drivers that are amenable for molecularly targeted therapies or to the improve disease classification through biomarker discovery.

Dr. Marc Remke studied medicine in Bonn, Freiburg, Cádiz (Spain) and Heidelberg and obtained his doctoral degree in 2009. Subsequently he worked as an assistant physician and as a postdoc at the university pediatric clinic and the German Cancer Research Center (DKFZ) in Heidelberg. 2012-2014 he worked as Postdoc at the Hospital for Sick Children in Toronto, Canada. Since 2014 he is a group leader as part of the German Cancer Consortium (DKTK) at its Essen/Düsseldorf site.

Distinctions and Awards
  • Research award in neuroonkology of the Sibylle Assmus Foundation, 2017
  • Ulrich Hadding Research Award of the Biomedical Research Center (BMFZ), 2016
  • Early Career Development Grant, 2015
  • Group leader within the German Cancer Consortium (DKTK), since 2014
  • Ontario Graduate Scholarship, Ministry of Training, Colleges and Universities (MTCU) awarded by the University of Toronto, 2014
  • Walther and Christine Richtzenhain Award, German Cancer Research Center (DKFZ), 2012
  • Young Investigator Award, German National Academy of Sciences Leopoldina, 2011
  • Lina Marguerite Siebert Award, Pediatric Cancer Foundation Mainz, 2011
  • Selma-Meyer-Thesis Award, German Society of Pediatric and Adolescent Medicine (DGKJ), 2010
  • Desitin Young Investigator Award, German Society of Neuropediatrics (DGN), 2010
  • Annual Sponsorship Award for Outstanding Doctoral Thesis, German Society of Hematology & Oncology (DGHO), 2009
  • Dr. Maresch-Klingelhöffer Award (shared with S. M. Pfister and W.G. Janzarik), Pediatric Cancer Foundation Frankfurt, 2008
  • Intramural scholarship for medical students, German Cancer Research Center (DKFZ), 2007
  • Scholarship, Konrad-Adenauer-Foundation, 2003-2009
Key publications

Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 Jun;131(6):821-31

Shih D.J.*, Northcott P.A.*, Remke M.* et al., …, and Pfister, S.M., Taylor, M.D. Cytogenetic Prognostication Within Medulloblastoma Subgroups. J Clin Oncol. 2014 Mar 20;32(9):886-96

Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, Kushida M, Head R, Morrissy S, Zhu X, Aviv T, Voisin V, Clarke ID, Li Y, Mungall AJ, Moore RA, Ma Y, Jones SJ, Marra MA, Malkin D, Northcott PA, Kool M, Pfister SM, Bader G, Hochedlinger K, Korshunov A, Taylor MD, Dirks PB. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell. 2014 Jul 14;26(1):33-47

Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Somasekharan SP, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013 May 23;153(5):1064-79

Remke M*, Hielscher T*, Korshunov A, Northcott PA, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren AO, von Deimling A, Rutkowski S, Scheurlen W, Kulozik AE, Taylor MD, Lichter P, Pfister SM. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011 Oct 10;29(29):3852-61

Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 1;29(19):2717-23.

* shared first author

 

Photo: private

Responsible for the content: Junior Scientist and International Researcher Center